Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Single-Center, Randomized, 5-Way Crossover Study to Compare the Safety, Tolerability and Pharmacokinetics of New Oral Cannabinoid Formulations Administered as Single Doses, With Buccal Sativex®, in Healthy Volunteers

Trial Profile

A Single-Center, Randomized, 5-Way Crossover Study to Compare the Safety, Tolerability and Pharmacokinetics of New Oral Cannabinoid Formulations Administered as Single Doses, With Buccal Sativex®, in Healthy Volunteers

Completed
Phase of Trial: Phase I

Latest Information Update: 01 Oct 2018

At a glance

  • Drugs Cannabidiol (Primary) ; Cannabidiol/tetrahydrocannabivarin-9 (Primary) ; Nabiximols; Nabiximols
  • Indications Multiple sclerosis
  • Focus Adverse reactions
  • Sponsors PhytoTech Therapeutics
  • Most Recent Events

    • 01 Oct 2018 Results published in the Clinical Pharmacology in Drug Development
    • 30 Jun 2017 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top